Introducing PulmiORA
PulmiORA is designed to address two of the most serious and fast-growing respiratory diseases worldwide—Lung Fibrosis and Chronic Obstructive Pulmonary Disease (COPD). Together, these conditions represent a massive global health burden and a significant unmet medical need, creating strong momentum for innovation, partnership, and investment.
An innovative aerosol-based medicine invented in India, bringing hope to millions of people suffering from COPD and Lung Fibrosis worldwide through a breakthrough first-in-class mechanism.
First-in-class mechanism: Denatures genetic material by oxidizing the guanine base of all stains of bacteria, fungus, and viruses in the respiratory system.
Advanced aerosol delivery system ensures optimal drug distribution throughout the respiratory tract with precise dosing control.
With a cure: Patients could regain near-normal lung capacity and oxygen exchange efficiency, reversing years of respiratory decline.
Most economical and safe with almost nil side effects compared to existing steroidal and antibiotic therapies. Highly patient compliant.
Stops frequent exacerbations which currently accelerate lung decline. Prevents lung tissue degradation, alveolar collapse, and airway inflammation.
Used 15 min once in a week as post exposure preventive for respiratory viral infections. Protects against seasonal respiratory infections.
A patient-friendly regimen designed for maximum efficacy and compliance.
Minutes per session
Hours between doses
Days total treatment
PulmiORA's carefully calibrated dosing regimen ensures maximum therapeutic benefit with optimal safety.
15 minutes every 4 hours for 3-5 days. Short treatment course kills all types of bacteria, fungal fibrosis, and all stains of viruses in the respiratory system through controlled nebulization.
15 minutes once weekly as post-exposure preventive therapy for respiratory viral infections. Provides ongoing protection during flu season and high-risk periods.
Inhaled through nebulizer with controlled aerosol delivery. The aqueous chlorine solution is precisely nebulized for optimal respiratory tract coverage and absorption.
High adherence rate due to simple protocol, minimal side effects, and rapid symptom improvement. Patients report excellent tolerance and satisfaction.
Targeting COPD and Lung Fibrosis at their core – not just the symptoms. A disruptive novel drug with a first-in-class therapeutic approach.
in Respiratory System
Oxidises The Guanine Base
Kills All Stains of
Fungus, Bacteria & Viruses
in Pulmonary System.
in Respiratory System
Healthy Pulmonary System
PulmiORA oxidizes the guanine base in pathogen DNA/RNA, causing irreversible genetic material denaturation. This novel mechanism prevents bacterial, viral, and fungal replication at the molecular level.
The treatment specifically targets viruses, bacteria and fungus in pulmonary system while preserving human cellular integrity. The selectivity ensures therapeutic efficacy without damage to healthy Pulmonary Tissues
Effective against all types of bacteria, all strains of viruses, and fungal fibrosis. Universal mechanism eliminates need for pathogen identification before treatment initiation.
The active aqueous chlorine solution is safely delivered via controlled nebulization, providing antimicrobial action with minimal systemic absorption and virtually no side effects.
Understanding how PulmiORA's revolutionary approach differs from traditional COPD and Lung Fibrosis therapies.
Temporarily Relief With Severe Side Effects
Bronchodilators, Steroidal Medicines (Corticosteroids), Antibiotics, Antifibrotics, etc. are having Severe Long Term Side Effects to Human Body.
Suppress the disease temporarily, relieve symptoms and slow progression.
Cures Lung Fibrosis & COPD With Nil Side Effects
15 min. Nebulization of PulmiORA as per the Prescribed Dosage i.e. 15 min every 4 hr for 3 to 5 Days Kills All Stains of Viruses, Bacteria's and Fungal Fibrosis Without any Side Effects in the Body.
CURES the disease and used as a PREVENTIVE therapy without any side effect to human body.
Patients regain near-normal lung capacity and oxygen exchange efficiency
Stops frequent flare-ups that accelerate COPD and Lung Fibrosis progression and lung decline
Most economical COPD and Lung Fibrosis treatment globally with high therapeutic value
Simple 15-minute protocol ensures excellent patient adherence rates
Proudly invented in India to serve global COPD and Lung Fibrosis patients
Weekly 15-min sessions prevent respiratory viral infections
PulmiORA ground breaking First-in-Class mechanism for treating Respiratory Viral infection through Controlled nebullization oxidises the Guanine Base is legally protected in India.
Pub. No.: US 2021/0401876 A1
Published: Dec. 30, 2021
Pharmaceutical composition of chlorine for treatment of respiratory viral infection, including COVID and viral morbidities.
Contact us to learn more about partnership opportunities and how to bring this breakthrough treatment to your patients.
Get in Touch